Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUSION Regimen with Ranibizumab in Exudative AMD
NCT01500915Phase 4Completed
- Sponsor
- Institut de la Màcula
- Start
- Nov 2010
- Primary completion
- Mar 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in exudative age-related macular degeneration, sponsored by Institut de la Màcula. Started Nov 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01500915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500915.